abstract |
The present invention relates to Epstein-Barr virus antigen polynucleotides, polypeptides and vectors; In addition, it provides an immunogenic composition comprising the same. The present invention encompasses the use of an Epstein-Barr virus antigen construct for the production of vaccines for the treatment and prevention of Epstein-Barr virus infections and Epstein-Barr virus-associated diseases such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus. . |